Cited 25 times in
Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태현 | - |
dc.contributor.author | 박소희 | - |
dc.contributor.author | 박은철 | - |
dc.contributor.author | 이상규 | - |
dc.date.accessioned | 2016-02-04T11:31:48Z | - |
dc.date.available | 2016-02-04T11:31:48Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/140631 | - |
dc.description.abstract | OBJECTIVES: To evaluate the quantitative effects of the drug price reduction on pharmaceutical expenditures and the new guidelines to restrict prescribing on drug utilisation for antihypertensive drugs. DESIGN: We used an interrupted time series design with the National patient sample data of Health Insurance Review and Assessment Service in South Korea. METHODS: 54,295 participants who were with primary hypertension from the National patient sample data of Health Insurance Review and Assessment Service were included. The study period was from March 2011 to December 2013. The dependent variables were antihypertensive drug costs, antihypertensive drug cost per prescribing day, daily drug utilisation, average number of drugs per month, percentage of original drugs per prescription, drug overutilisation and prohibited combinations. Segmented regression analysis was used. RESULTS: The drug price reduction reduced expenditure (US$-1.51, -10.2%), and the new guidelines reduced expenditures even more (US$-2.13; -16.2%). These policies saved US$4.22 (28%) of antihypertensive drug costs per patient in December 2013 compared to March 2012. Drug price reduction policy was introduced in April 2012. We established the policy effect by comparing it before (March 2012) with after(21 months later-December 2012). The effects of the guidelines decreased expenditures, daily drug utilisation and the average number of drugs per month more than did the drug price reduction. CONCLUSIONS: Both policies saved money. The guidelines were more effective over time and had fewer side effects such as increasing daily drug utilisation and number of drugs than the effects of drug price reduction. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | BMJ OPEN | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antihypertensive Agents/economics* | - |
dc.subject.MESH | Drug Costs/trends* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Health Expenditures/trends* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Insurance, Health, Reimbursement/legislation & jurisprudence* | - |
dc.subject.MESH | Interrupted Time Series Analysis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Practice Guidelines as Topic/standards* | - |
dc.subject.MESH | Regression Analysis | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Preventive Medicine (예방의학) | - |
dc.contributor.googleauthor | Ki-Bong Yoo | - |
dc.contributor.googleauthor | Sang Gyu Lee | - |
dc.contributor.googleauthor | Sohee Park | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Jeonghoon Ahn | - |
dc.contributor.googleauthor | Mee-Hyun Cho | - |
dc.contributor.googleauthor | Eun-Cheol Park | - |
dc.identifier.doi | 10.1136/bmjopen-2014-006940 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02811 | - |
dc.contributor.localId | A01082 | - |
dc.contributor.localId | A01531 | - |
dc.contributor.localId | A01618 | - |
dc.relation.journalcode | J00380 | - |
dc.identifier.eissn | 2044-6055 | - |
dc.identifier.pmid | 26179644 | - |
dc.subject.keyword | antihypertensive drug | - |
dc.subject.keyword | direct price control | - |
dc.subject.keyword | drug utilization | - |
dc.subject.keyword | pharmaceutical expenditures | - |
dc.subject.keyword | reimbursement restriction | - |
dc.contributor.alternativeName | Kim, Tae Hyun | - |
dc.contributor.alternativeName | Park, So Hee | - |
dc.contributor.alternativeName | Park, Eun Chul | - |
dc.contributor.alternativeName | Lee, Sang Gyu | - |
dc.contributor.affiliatedAuthor | Lee, Sang Gyu | - |
dc.contributor.affiliatedAuthor | Kim, Tae Hyun | - |
dc.contributor.affiliatedAuthor | Park, So Hee | - |
dc.contributor.affiliatedAuthor | Park, Eun Chul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 5 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 006940 | - |
dc.identifier.bibliographicCitation | BMJ OPEN, Vol.5(7) : 006940, 2015 | - |
dc.identifier.rimsid | 30214 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.